We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-0.94%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$498M
AUM Growth
-$33M
Cap. Flow
+$1.65M
Cap. Flow %
0.33%
Top 10 Hldgs %
75.53%
Holding
33
New
4
Increased
9
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$14.8M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$12.9M
3
FATE icon
Fate Therapeutics
FATE
+$10.1M
4
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$3.54M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.96M

Top Sells

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$15.9M
2
ARRY
Array Biopharma Inc
ARRY
+$10.9M
3
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$9.87M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.92M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 76.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
26
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.28M 0.26%
734,976
– –
XOMA
27
DELISTED
Xoma
XOMA
$1.28M 0.26%
+302,800
New +$1.88M
ANTH
28
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$40K 0.01%
+7,787
New +$135K
GYRE icon
29
Gyre Therapeutics
GYRE
$648M
– –
-7,696
Closed -$1.05M
PTGX icon
30
Protagonist Therapeutics
PTGX
$8.92B
– –
-375,000
Closed -$7.92M
TBRA
31
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-399,433
Closed -$15.9M
GBIM
32
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
– –
-657,653
Closed -$822K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2016 Portfolio in Review

As of Q4 2016, BVF Inc held 33 positions worth $498M, down 6.2% from $531M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

BVF Inc's Q4 2016 filing shows 4 new, 9 increased, 10 reduced and 4 closed positions. Its largest new stake was Achillion Pharmaceuticals: 2,423,300 shares worth $10M. The largest sale was Tobira Therapeutics, Inc. Common Stock, an estimated $15.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 78% a quarter earlier.

  • BVF Inc's largest Q4 2016 buy was Achillion Pharmaceuticals: 2,423,300 shares worth $10M.
  • BVF Inc added most to Blueprint Medicines in Q4 2016, an estimated $14.8M increase.
  • BVF Inc's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $10.9M.
  • BVF Inc fully exited Tobira Therapeutics, Inc. Common Stock in Q4 2016, selling an estimated $15.9M.
  • BVF Inc's ten largest holdings make up 76% of its $498M portfolio in Q4 2016.
  • BVF Inc opened 4 new positions and closed 4 in Q4 2016.
  • BVF Inc's portfolio value fell 6.2% quarter-over-quarter to $498M.

Based on BVF Inc's 13F filing for Q4 2016, filed 14 Feb 2017.